Page last updated: 2024-12-07

p(1),p(5)-di(adenosine-5'-)pentaphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

P(1),P(5)-di(adenosine-5'-)pentaphosphate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

P(1),P(5)-bis(5'-adenosyl) pentaphosphate(5-) : An organophosphate oxoanion arising from global deprotonation of the pentaphosphate OH groups of P(1),P(5)-bis(5'-adenosyl) pentaphosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID45479437
CHEBI ID62041
MeSH IDM0059200

Synonyms (10)

Synonym
bis(5'-adenosyl) pentaphosphate
p(1),p(5)-di(adenosine-5'-)pentaphosphate
5',5'''-diadenosine pentaphosphate
p1,p5-bis(5'-adenosyl) pentaphosphate
p1,p5-di(adenosine-5')-pentaphosphate
CHEBI:62041
adenosine(5')pentaphosphonato(5')adenosine(5-)
p(1),p(5)-bis(5'-adenosyl) pentaphosphate(5-)
3OTX
Q27131555

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" When the high-affinity adenosine receptors A(1) or A(2A) were activated, the Ap(5)A dose-response curves showed a high-affinity component with EC(50) values of 41."( Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation.
Cunha, RA; Díaz-Hernández, M; Miras-Portugal, MT; Pereira, MF; Pintor, J; Ribeiro, JA, 2002
)
0.31
"L(-1) cytosolic Ca2+, a significant 'hump' or plateau at the base of the dose-response relationship to Ap5A was revealed."( Diadenosine pentaphosphate is a potent activator of cardiac ryanodine receptors revealing a novel high-affinity binding site for adenine nucleotides.
Carter, SM; Chen, Y; Sitsapesan, R; Song, L, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organophosphate oxoanionAn organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
superpathway of adenosine nucleotides de novo biosynthesis I2424
UTP and CTP de novo biosynthesis1321
superpathway of pyrimidine ribonucleosides salvage2237
adenosine ribonucleotides de novo biosynthesis617
superpathway of pyrimidine nucleobases salvage1126
superpathway of pyrimidine ribonucleotides de novo biosynthesis2345
superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis4662

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Adenosine kinase, putativeTrypanosoma bruceiIC50 (µMol)29.400029.400029.400029.4000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011PLoS neglected tropical diseases, May, Volume: 5, Issue:5
Crystal structures of T. b. rhodesiense adenosine kinase complexed with inhibitor and activator: implications for catalysis and hyperactivation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (211)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (18.01)18.7374
1990's83 (39.34)18.2507
2000's61 (28.91)29.6817
2010's27 (12.80)24.3611
2020's2 (0.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.93%)5.53%
Reviews5 (2.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other208 (96.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]